ADVANCES IN TARGETED THERAPY AND IMMUNOTHERAPY FOR BREAST CANCER TREATMENT IN THE CONTEXT OF MODERN ONCOLOGY AND HEALTHCARE SYSTEMS

Dallo Salva Faekovna
Assistant, Department of Oncology, Oncohematology, and Radiation Oncology, Tashkent State Medical University, Tashkent, Uzbekistan

Abstract. *Breast cancer remains one of the most prevalent oncological diseases among women worldwide and represents a significant healthcare burden in many developing countries, including Uzbekistan. Despite improvements in early detection programs and conventional treatment strategies, mortality rates remain considerable due to tumor heterogeneity, late-stage diagnosis, and therapy resistance. In recent years, advances in molecular oncology have led to the development of targeted therapy and immunotherapy, fundamentally transforming breast cancer management.*

Targeted therapies are designed to selectively inhibit specific molecular pathways involved in tumor growth and progression. Agents targeting HER2 overexpression, CDK4/6 signaling, PI3K/AKT/mTOR pathways, and BRCA-associated DNA repair mechanisms have demonstrated improved progression-free survival and overall survival in defined patient subgroups. These therapies offer a more individualized approach compared to traditional cytotoxic chemotherapy, reducing systemic toxicity while enhancing treatment efficacy.

Immunotherapy, particularly immune checkpoint inhibitors targeting PD-1 and PD-L1 pathways, has introduced new therapeutic opportunities, especially for patients with triple-negative breast cancer, a subtype historically associated with poor prognosis and limited targeted treatment options. By activating the patient's immune system to recognize and destroy malignant cells, immunotherapy contributes to durable clinical responses in selected cases.

In the context of Uzbekistan and similar healthcare systems, the implementation of targeted therapy and immunotherapy presents both opportunities and challenges. Limited access to advanced molecular diagnostics, high treatment costs, and the need for specialized oncology infrastructure remain significant barriers. However, gradual integration of molecular testing, development of national oncology programs, and international collaboration may facilitate the broader adoption of precision medicine strategies.

This article aims to analyze recent advances in targeted therapy and immunotherapy for breast cancer treatment, evaluate their clinical effectiveness, and assess their relevance and applicability within emerging healthcare systems.

Keywords. *Breast cancer; targeted therapy; immunotherapy; HER2-positive breast cancer; CDK4/6 inhibitors; PARP inhibitors; immune checkpoint inhibitors; precision medicine; triple-negative breast cancer; oncology in Uzbekistan.*

Introduction

Breast cancer is the most frequently diagnosed malignancy among women globally and remains one of the leading causes of cancer-related mortality. According to global epidemiological data, its incidence continues to increase due to population aging, lifestyle changes, and improved diagnostic capabilities. In developing and transitional healthcare systems, including Uzbekistan, breast cancer represents a growing public health concern, particularly because a significant proportion of cases are diagnosed at advanced stages.

Traditional treatment strategies for breast cancer have historically relied on surgery, chemotherapy, radiotherapy, and endocrine therapy. While these modalities have contributed to improved survival rates, they are often associated with systemic toxicity, non-specific mechanisms of action, and the development of therapeutic resistance. Furthermore, breast cancer is a biologically heterogeneous disease composed of multiple molecular subtypes with distinct prognostic and therapeutic characteristics. This heterogeneity limits the effectiveness of uniform treatment approaches and highlights the need for individualized therapeutic strategies.

Advances in molecular biology and genomic profiling have significantly improved understanding of the genetic and signaling pathways involved in breast cancer progression. Identification of molecular subtypes—such as HER2-positive, hormone receptor–positive (luminal A and B), and triple-negative breast cancer—has enabled the development of targeted therapies aimed at specific molecular abnormalities. These therapies selectively inhibit oncogenic drivers responsible for tumor growth, offering improved efficacy and reduced systemic toxicity compared to conventional chemotherapy.

In recent years, immunotherapy has emerged as an innovative treatment modality in oncology. By modulating immune checkpoint pathways and enhancing antitumor immune responses, immunotherapeutic agents have demonstrated promising results, particularly in aggressive breast cancer subtypes such as triple-negative disease. Although the role of immunotherapy in breast cancer is still evolving, ongoing clinical trials continue to expand its therapeutic indications.

In the context of Uzbekistan, the integration of targeted therapy and immunotherapy into routine clinical practice remains a developing process. Limited availability of advanced molecular diagnostics, restricted access to high-cost biologic agents, and the need for specialized oncology training represent current challenges. Nevertheless, national oncology reforms, increasing investment in healthcare infrastructure, and international scientific collaboration are gradually improving access to precision oncology approaches.

Therefore, understanding the scientific basis, clinical effectiveness, and healthcare implications of targeted therapy and immunotherapy is essential for optimizing breast cancer management within modern and emerging healthcare systems. This article examines recent advances in these therapeutic strategies and evaluates their relevance for contemporary oncology practice.

Materials and Methods

This study was conducted as a structured analytical review of contemporary scientific literature focusing on advances in targeted therapy and immunotherapy for breast cancer treatment. The objective was to evaluate clinical effectiveness, mechanisms of action, resistance patterns, and applicability within developing healthcare systems, including the context of Uzbekistan.

A comprehensive literature search was performed using international scientific databases, including PubMed, Scopus, Web of Science, and ClinicalTrials.gov. The search strategy incorporated combinations of the following keywords: “breast cancer,” “targeted therapy,” “immunotherapy,” “HER2 inhibitors,” “CDK4/6 inhibitors,” “PARP inhibitors,” “PI3K inhibitors,” “immune checkpoint inhibitors,” “PD-1,” “PD-L1,” and “triple-negative breast cancer.” Boolean operators (AND, OR) were applied to refine and optimize search results.

Publications from 2010 to 2024 were prioritized to reflect recent clinical advances. Foundational landmark trials published earlier were included when they significantly contributed to the development of modern targeted or immunotherapeutic approaches. Eligible sources included randomized controlled trials, phase II–III clinical studies, meta-analyses, systematic reviews, and clinical guidelines issued by recognized oncology organizations.

Inclusion criteria consisted of:

1. Studies evaluating targeted or immunotherapeutic agents in breast cancer treatment;
2. Clinical trials reporting measurable outcomes such as overall survival (OS), progression-free survival (PFS), objective response rate (ORR), or safety profiles;
3. Research addressing mechanisms of drug resistance or biomarker-guided patient selection.

Exclusion criteria included non-peer-reviewed publications, preclinical studies without clinical correlation, incomplete trial reports, and articles lacking clear methodological description.

Data extraction focused on therapeutic class, mechanism of action, molecular targets, patient subgroup characteristics, survival outcomes, adverse effects, and resistance mechanisms. Additionally, considerations regarding accessibility, cost, and healthcare infrastructure requirements were analyzed to assess potential implementation challenges in emerging healthcare systems.

The collected data were synthesized qualitatively to identify consistent therapeutic trends, clinical benefits, limitations, and future research directions in the field of precision oncology for breast cancer.

Results

The analysis of contemporary clinical studies demonstrated that targeted therapy and immunotherapy have significantly improved treatment outcomes in selected molecular subtypes of breast cancer.

HER2-targeted therapies, including monoclonal antibodies and tyrosine kinase inhibitors, showed substantial improvements in progression-free survival (PFS) and overall survival

(OS) among patients with HER2-positive breast cancer. Combination regimens integrating anti-HER2 agents with chemotherapy or dual HER2 blockade demonstrated higher objective response rates compared to standard chemotherapy alone. Long-term follow-up data confirmed durable clinical benefit, particularly in early-stage and metastatic settings.

In hormone receptor–positive (HR+) breast cancer, CDK4/6 inhibitors combined with endocrine therapy significantly prolonged progression-free survival compared to endocrine therapy alone. Clinical trials consistently reported improved disease control rates and delayed resistance development. Similarly, PI3K and mTOR pathway inhibitors provided clinical benefit in patients with endocrine-resistant disease, especially in those harboring PIK3CA mutations.

PARP inhibitors demonstrated marked efficacy in patients with germline BRCA1 or BRCA2 mutations. These agents improved progression-free survival in metastatic breast cancer and showed manageable safety profiles. The therapeutic principle of synthetic lethality proved particularly effective in BRCA-mutated tumors characterized by defective DNA repair mechanisms.

Immunotherapy, particularly immune checkpoint inhibitors targeting PD-1 and PD-L1 pathways, showed promising results in triple-negative breast cancer (TNBC). Clinical trials combining checkpoint inhibitors with chemotherapy reported improved progression-free survival in PD-L1–positive TNBC patients. However, the magnitude of benefit varied depending on biomarker expression and tumor microenvironment characteristics.

Despite these advances, resistance to targeted and immunotherapeutic agents remains a major clinical challenge. Mechanisms of resistance included secondary genetic mutations, activation of alternative signaling pathways, tumor microenvironment modulation, and immune escape mechanisms. Adverse effects such as cardiotoxicity (HER2-targeted therapy), neutropenia (CDK4/6 inhibitors), hyperglycemia (PI3K inhibitors), and immune-related adverse events (checkpoint inhibitors) were reported but were generally manageable with appropriate monitoring.

In the context of emerging healthcare systems, access to molecular testing and high-cost biologic therapies remains variable. While clinical efficacy is well established in global trials, implementation depends on healthcare infrastructure, availability of diagnostic technologies, and national oncology policy frameworks.

Overall, the results indicate that targeted therapy and immunotherapy have transformed breast cancer management by improving survival outcomes, especially in molecularly defined patient populations. However, optimizing patient selection and overcoming resistance remain critical areas for future research.

Discussion

The results of this review confirm that targeted therapy and immunotherapy have fundamentally transformed the treatment landscape of breast cancer. Unlike conventional chemotherapy, which exerts non-specific cytotoxic effects, modern precision therapies are designed to interfere with defined molecular drivers of tumor growth. This paradigm shift has

led to improved survival outcomes, better tolerability profiles, and more individualized treatment strategies.

HER2-targeted therapies represent one of the earliest and most successful examples of precision oncology in breast cancer. Long-term clinical data demonstrate that dual HER2 blockade and antibody–drug conjugates significantly reduce recurrence rates and improve overall survival. These outcomes highlight the importance of accurate molecular diagnostics, as therapeutic benefit is closely linked to biomarker expression.

Similarly, the introduction of CDK4/6 inhibitors has substantially changed the management of hormone receptor–positive breast cancer. By targeting cell cycle dysregulation, these agents delay disease progression and extend the effectiveness of endocrine therapy. The integration of PI3K and mTOR inhibitors further supports a multi-pathway treatment approach, particularly in endocrine-resistant cases.

PARP inhibitors illustrate the clinical application of synthetic lethality in BRCA-mutated tumors. Their effectiveness underscores the necessity of genetic testing in guiding therapeutic decisions. However, expanding access to molecular diagnostics remains a significant challenge in developing healthcare systems.

Immunotherapy has introduced new possibilities, especially for triple-negative breast cancer, a subtype historically associated with limited treatment options. Although response rates are modest compared to other malignancies such as melanoma or lung cancer, the durability of response in selected PD-L1–positive patients is clinically meaningful. Ongoing research aims to identify predictive biomarkers and optimize combination regimens to enhance response rates.

Despite these advances, several limitations persist. Drug resistance mechanisms, including pathway reactivation and tumor microenvironment adaptation, reduce long-term efficacy. Additionally, immune-related adverse events and organ-specific toxicities require careful monitoring and multidisciplinary management. Economic factors also play a crucial role, as high costs limit accessibility in resource-constrained healthcare systems.

In the context of Uzbekistan and similar emerging healthcare environments, gradual integration of targeted therapy and immunotherapy depends on strengthening oncology infrastructure, expanding molecular testing capabilities, training healthcare professionals, and developing national reimbursement strategies. International collaboration and participation in multicenter clinical trials may further facilitate access to innovative therapies.

Overall, the transition toward precision oncology represents a critical advancement in breast cancer treatment. Continued research focusing on resistance mechanisms, biomarker discovery, and cost-effective implementation strategies will be essential for maximizing clinical benefits across diverse healthcare settings.

Conclusion

Advances in targeted therapy and immunotherapy have significantly reshaped the modern management of breast cancer. By focusing on specific molecular pathways and immune regulatory mechanisms, these treatment strategies provide more precise, effective, and

individualized therapeutic options compared to conventional chemotherapy. HER2-targeted agents, CDK4/6 inhibitors, PI3K/mTOR inhibitors, and PARP inhibitors have demonstrated substantial improvements in progression-free and overall survival in well-defined molecular subgroups. In addition, immune checkpoint inhibitors have opened new therapeutic possibilities, particularly for patients with triple-negative breast cancer.

The success of these innovative therapies highlights the critical importance of molecular diagnostics, biomarker identification, and personalized treatment planning. However, challenges such as acquired drug resistance, treatment-related toxicities, high costs, and limited accessibility in developing healthcare systems remain significant barriers to widespread implementation.

In emerging healthcare contexts, including Uzbekistan, the gradual integration of precision oncology requires strengthening diagnostic infrastructure, expanding access to genetic testing, improving oncological training, and establishing sustainable financing mechanisms. Strategic healthcare reforms and international scientific collaboration may facilitate broader adoption of advanced therapeutic technologies.

In conclusion, targeted therapy and immunotherapy represent essential components of contemporary breast cancer treatment. Continued clinical research, optimization of combination strategies, and equitable healthcare development will be crucial for improving long-term patient outcomes and ensuring that the benefits of modern oncology are accessible across diverse healthcare systems.

References

1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2020). Global cancer statistics 2020. CA: A Cancer Journal for Clinicians, 70(4), 313–331.

2. Sung, H., Ferlay, J., Siegel, R. L., et al. (2021). Global cancer statistics 2021. CA: A Cancer Journal for Clinicians, 71(3), 209–249.

3. Slamon, D. J., Clark, G. M., Wong, S. G., et al. (1987). Human breast cancer: Correlation of relapse and survival with HER2 amplification. Science, 235(4785), 177–182.

4. Swain, S. M., Baselga, J., Kim, S. B., et al. (2015). Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. New England Journal of Medicine, 372, 724–734.

5. Эргашев, Н. Ш., & Саттаров, Ж. Б. (2014). Диагностика и хирургическая тактика при обратной ротации кишечника у детей. Детская хирургия, 18(3), 29-32.

6. Sattarov, J., & Nazarov, N. (2020). Features of the clinic, diagnosis and treatment of mesocolic-parietal hernias in newborns and children of elder age groups. Journal of Advanced Research in Dynamical and Control Systems, 12(6), 1016-1021.

7. Саттаров, Ж. Б., & Бобоев, М. Ш. (2025). ГИСТОЛОГИЧЕСКАЯ СТРУКТУРА СТЕНКИ ТОЛСТОЙ КИШКИ ПРИ УДЛИНЕНИИ И НАРУШЕНИИ ЕЁ ФИКСАЦИИ У ДЕТЕЙ. Eurasian Journal of Medical and Natural Sciences, 5(10-2), 84-92.

8. Бобоев, М. Ш., & Саттаров, Ж. Б. (2025). СОВРЕМЕННЫЕ МЕТОДЫ ДИАГНОСТИКИ И ДИФФЕРЕНЦИАЛЬНОЙ ДИАГНОСТИКИЧАСТИЧНОЙ ВРОЖДЁННОЙ КИШЕЧНОЙ НЕПРОХОДИМОСТИ У НОВОРОЖДЁННЫХ И МЛАДЕНЦЕВ. Eurasian Journal of Medical and Natural Sciences, 5(10-2), 76-83.

9. Эргашев, Н. Ш., Саттаров, Ж. Б., & Эргашев, Б. Б. (2015). Синдром Ледда у новорожденных. Детская хирургия, 19(2), 26-29.

10. Саттаров, Ж. Б., & Бобоев, М. Ш. (2025). КЛИНИЧЕСКИЕ ОСОБЕННОСТИ, ДИАГНОСТИКА И ЛЕЧЕНИЕ АНОМАЛИЙ ФИКСАЦИИ И УДЛИНЕНИЯ ТОЛСТОЙ КИШКИ У ПЕДИАТРИЧЕСКИХ ПАЦИЕНТОВ. Eurasian Journal of Medical and Natural Sciences, 5(10-2), 93-101.

11. Саттаров, Ж., & Хуррамов, Ф. (2019). Ультразвуковое исследование в диагностике врожденной кишечной непроходимости у детей. Журнал вестник врача, 1(3), 94-98.

12. Эргашев, Н. Ш., & Саттаров, Ж. Б. (2013). Диагностика и лечение врожденной кишечной непроходимости у новорожденных. Современная медицина: актуальные вопросы, (25), 58-65.

13. Sh, B. M. (2025). Cystic duplication of the stomach in children. Web of Medicine: Journal of Medicine. Practice and Nursing, 3(1), 367-371.

14. Хуррамов, Ф. М., Саттаров, Ж. Б., Хамидов, Б., & Хайдаров, Н. С. (2024). Болаларда корин бушлоти битишма касаллиги. Педиатрия журнали, (1), 553-559.

15. Fayzieva, N., & Abrorxo’ja, R. (2025). INTEGRATION OF BIOPHYSICS AND INFORMATION TECHNOLOGIES FOR MODELING HUMAN BIOMECHANICAL MOVEMENTS USING 3D SENSORS AND MACHINE LEARNING. Eureka Journal of Health Sciences & Medical Innovation, 1(2), 54-68.

16. Nodira, F. (2018). Specificity of interaction between teacher and students in the process of teaching a foreign language. Вопросы науки и образования, (8 (20)), 141-143.

17. Alisherovna, K. S. S. F. N., Amanaliyevich, O. N., & Polatovich, K. S. (2025). MECHANISMS OF IONIZING RADIATION-INDUCED DAMAGE TO CELLS AND DNA. SHOKH LIBRARY, 1(13).

18. Dusaliyev, F. M., & Sh, B. M. (2026). CLINICAL COURSE AND DIAGNOSTIC APPROACHES OF ANORECTAL MALFORMATIONS ASSOCIATED WITH RECTOURETHRAL FISTULAS IN BOYS. Shokh Articles Library, 1(1).

19. Sh, B. M. (2025). HOMILA ICHI MEKONIYALI PERITONITIN TEKSHIRISH VA DAVOLASHNI TAKOMILASHTIRISH (ADABIYOTLAR SHARHI). Central Asian Journal of Academic Research, 3(11-2), 142-148.

20. Бобоев, М. Ш., & Хайдаров, Н. С. (2025). СИНДРОМ ОБЪЁМНОГО ОБРАЗОВАНИЯ БРЮШНОЙ ПОЛОСТИ У ДЕТЕЙ. Eurasian Journal of Medical and Natural Sciences, 5(10-2), 174-181.

21. Khaidarov, N. S., Sh, B. M., & Dusaliyev, F. M. (2026). POSTOPERATIVE ABDOMINAL ADHESIVE DISEASE IN CHILDREN: CLINICAL EXPERIENCE. Shokh Articles Library, 1(1).

22. Саттаров, Ж. Б., & Бобоев, М. Ш. (2025). ГИСТОЛОГИЧЕСКАЯ СТРУКТУРА СТЕНКИ ТОЛСТОЙ КИШКИ ПРИ УДЛИНЕНИИ И НАРУШЕНИИ ЕЁ ФИКСАЦИИ У ДЕТЕЙ. Eurasian Journal of Medical and Natural Sciences, 5(10-2), 84-92.

23. Бобоев, М. Ш., & Саттаров, Ж. Б. (2025). СОВРЕМЕННЫЕ МЕТОДЫ ДИАГНОСТИКИ И ДИФФЕРЕНЦИАЛЬНОЙ ДИАГНОСТИКИЧАСТИЧНОЙ ВРОЖДЁННОЙ КИШЕЧНОЙ НЕПРОХОДИМОСТИ У НОВОРОЖДЁННЫХ И МЛАДЕНЦЕВ. Eurasian Journal of Medical and Natural Sciences, 5(10-2), 76-83.

24. Бобоев, М. Ш., & Саттаров, Ж. Б. (2025). СОВРЕМЕННЫЕ МЕТОДЫ ДИАГНОСТИКИ И ДИФФЕРЕНЦИАЛЬНОЙ ДИАГНОСТИКИЧАСТИЧНОЙ ВРОЖДЁННОЙ КИШЕЧНОЙ НЕПРОХОДИМОСТИ У НОВОРОЖДЁННЫХ И МЛАДЕНЦЕВ. Eurasian Journal of Medical and Natural Sciences, 5(10-2), 76-83.

25. Sh, B. M. (2025). YANGI TUG ‘ILGAN CHAQALOQLAR VA GO ‘DAKLARDA UCHRAYDIGAN QISMAN TUG ‘MA ICHAK TUTILISHINI ZAMONAVIY DIAGNOSTIK TAKTIKASINI TANLASH. Central Asian Journal of Academic Research, 3(11-2), 136-141.

26. Саттаров, Ж. Б., & Бобоев, М. Ш. (2025). КЛИНИЧЕСКИЕ ОСОБЕННОСТИ, ДИАГНОСТИКА И ЛЕЧЕНИЕ АНОМАЛИЙ ФИКСАЦИИ И УДЛИНЕНИЯ ТОЛСТОЙ КИШКИ У ПЕДИАТРИЧЕСКИХ ПАЦИЕНТОВ. Eurasian Journal of Medical and Natural Sciences, 5(10-2), 93-101.

27. Sh, B. M. (2025). Intrauterine meconium peritonitis (literature review). Eurasian Journal of Medical and Natural Sciences, 5(10-2), 46-51.

28. Sh, B. M. (2025). Cystic duplication of the stomach in children. Web of Medicine: Journal of Medicine. Practice and Nursing, 3(1), 367-371.

29. Турсунова, О. А., & Шарапов, Б. У. (2017). ИЗУЧЕНИЕ ЧАСТОТЫ ЗАБОЛЕВАЕМОСТИ ГЕМОРРАГИЧЕСКИМ ВАСКУЛИТОМ У ДЕТЕЙ. In INTERNATIONAL INNOVATION RESEARCH (pp. 236-239).

30. Шарипова, З. У., Ашурова, Д. Т., & Турсунова, О. А. (2017). Эффективность ступенчатой антибактериальной терапии в лечении пневмонии у детей. Молодой ученый, (16), 102-104.

31. Ашурова, Д. Т., & Садирходжаева, А. А. (2018). Особенности клинической симптоматики поражения сердечно-сосудистой системы при СД 1 типа у детей. Проблемы науки, (2 (26)), 69-73.

32. Садирходжаева, А. А., & Ашурова, Д. Т. (2019). Особенности ранней диагностики диабетической кардиомиопатии во взаимосвязи с кардиологическими маркёрами у детей с сахарным диабетом 1. Уральский медицинский журнал, (8), 22-24.

33. Садирходжаева, А. А., Ашурова, Д. Т., & Шарапов, Б. У. (2019). ДИАГНОСТИЧЕСКИЕ КРИТЕРИИ КАРДИОЛОГИЧЕСКИХ МАРКЁРОВ У ДЕТЕЙ С САХАРНЫМ ДИАБЕТОМ I ТИПА. Новый день в медицине, (2), 50-52.

34. Садирходжаева, А. А., & Ашурова, Д. Т. (2019). Особенности состояния кардиологических маркёров в ранней диагностики диабетической кардиомиопатии у детей с сахарным диабетом 1 типа. Austrian Journal of Technical and Natural Sciences, (3-4), 3-7.

35. Садирходжаева, А. А., & Ашурова, Д. Т. (2022). hs-CRP в сыворотке крови как маркер асептического воспаление стенок сосудов у детей с сахарным диабетом 1 типа. In Молодые ученые-медицине (pp. 109-113).

36. Ахмедова, Д. И., Ишниязова, Н. Д., Салихова, Г. У., & Ашурова, Д. Т. (2012). Особенности психологического развития детей дошкольного возраста. Педиатрия. Илмий-амалий журнал, 38.

37. Ахмедова, Д. И., & Ашурова, Д. Т. (2012). Влияние интегрированного подхода по профилактике микронутриентной недостаточности на некоторые показатели физического развития детей в возрасте 3 лет Республики Каракалпакстан. Педиатрия. Илмий-амалий журнал, 34.

38. Садирходжаева, А. А., Турсунова, О. А., & Шарипова, З. У. (2018). Влияние кислородтранспортной системы крови на тканевую гипоксию у детей с сахарным диабетом I типа. Молодой ученый, (8), 48-51.

39. Piccart, M., Procter, M., Fumagalli, D., et al. (2016). Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. New England Journal of Medicine, 375, 122–131.

40. Verma, S., Miles, D., Gianni, L., et al. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. New England Journal of Medicine, 367, 1783–1791.

41. Finn, R. S., Crown, J. P., Lang, I., et al. (2015). The cyclin-dependent kinase 4/6 inhibitor palbociclib in HR-positive advanced breast cancer. New England Journal of Medicine, 373, 209–219.

42. Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., et al. (2016). Ribociclib as first-line therapy for HR-positive breast cancer. New England Journal of Medicine, 375, 1738–1748.

43. Sledge, G. W., Toi, M., Neven, P., et al. (2017). MONARCH 2: Abemaciclib in HR-positive advanced breast cancer. Journal of Clinical Oncology, 35(25), 2875–2884.

44. Robson, M., Im, S. A., Senkus, E., et al. (2017). Olaparib for metastatic breast cancer in patients with germline BRCA mutation. New England Journal of Medicine, 377, 523–533.

45. Tutt, A., Garber, J. E., Kaufman, B., et al. (2021). Adjuvant olaparib for patients with BRCA-mutated breast cancer. New England Journal of Medicine, 384, 2394–2405.

46. André, F., Ciruelos, E., Rubovszky, G., et al. (2019). Alpelisib for PIK3CA-mutated, HR-positive advanced breast cancer. New England Journal of Medicine, 380, 1929–1940.

47. Baselga, J., Campone, M., Piccart, M., et al. (2012). Everolimus in HR-positive advanced breast cancer. New England Journal of Medicine, 366, 520–529.

48. Schmid, P., Adams, S., Rugo, H. S., et al. (2018). Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. New England Journal of Medicine, 379, 2108–2121.

49. Cortes, J., Cescon, D. W., Rugo, H. S., et al. (2020). Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. New England Journal of Medicine, 382, 810–821.

50. Emens, L. A. (2018). Breast cancer immunotherapy: Facts and hopes. Clinical Cancer Research, 24(3), 511–520.

51. Denkert, C., Liedtke, C., Tutt, A., & von Minckwitz, G. (2017). Molecular alterations in triple-negative breast cancer. The Lancet, 389(10087), 2430–2442.

52. Turner, N. C., & Reis-Filho, J. S. (2012). Genetic heterogeneity and cancer drug resistance. The Lancet Oncology, 13(4), e178–e185.

53. Hanahan, D. (2022). Hallmarks of cancer: New dimensions. Cancer Discovery, 12(1), 31–46.

54. Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020). Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell, 27(4), 450–461.